date:Aug 08, 2012
ement ingredient, the FSA said it would take no further action until the MHRA completed its own investigation, apparently now into one particular product.
An independent advisory panel has been asked by the MHRA to advise whether a certain product containing DMAA should be classed as an unlicensed medicine and therefore subject to medicine controls,the FSA wrote in yesterdays missive.
This advice may also have implications for the status of other DMAA-containing supplements.
The MHRA would no